Finite-Lived Intangible Assets by Major Class [Axis]
Trade Name [Member]
Award Type [Axis]
Restricted Stock Units [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Klarity License Agreement [Member]
Title of Individual [Axis]
Richard L. Lindstrom, M.D [Member]
Licenses [Member]
Product and Service [Axis]
Product Sales, Net [Member]
License Revenues [Member]
Patents [Member]
Customer Relationships [Member]
Non-Competition Clause [Member]
Andrew R. Boll [Member]
John P. Saharek [Member]
Sales Agreement [Member]
Stock Option Plan [Member]
Unvested RSUs [Member]
Consultants, Employees and Directors [Member]
Options Granted to Employees [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Class of Warrant or Right [Axis]
Warrants [Member]
Employees [Member]
Income Statement Location [Axis]
Selling, General and Administrative [Member]
Directors [Member]
Consultants [Member]
Legal Entity [Axis]
Eton Pharmaceuticals, Inc. [Member]
Related Party [Axis]
Surface Pharmaceuticals [Member]
Eton Pharmaceuticals [Member]
Sales and Marketing Agreements [Member]
Non Employee Directors [Member]
Surface Pharmaceuticals, Inc [Member]
Management Services Agreement [Member]
Equity Components [Axis]
Common Stock Warrants [Member]
Common Stock Warrant One [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Lender Warrants [Member]
SWK Warrants [Member]
Measurement Input Type [Axis]
Expected Term [Member]
Dividend Rate [Member]
Risk Free Interest Rate [Member]
Scenario [Axis]
Initial Payment [Member]
License Agreement [Member]
Second Payment [Member]
Final Payment [Member]
Settlement Agreement [Member]
Concentration Risk Type [Axis]
Three Main Suppliers [Member]
Volatility [Member]
Amended and Restated Certificate of Incorporation [Member]
Previously Authorized Shares [Member]
Stock Option Plan [Member]
Corporate [Member]
Research and Development Expense [Member]
Sale of Stock [Axis]
IPO [Member]
Debt Instrument [Axis]
Note Payable [Member]
Exercise Price Range [Axis]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Settlement Warrants [Member]
Lender Warrants One [Member]
Melt Pharmaceuticals [Member]
Total Harrow Health, Inc. Stockholders' Equity [Member]
Total Noncontrolling Interests [Member]
Melt Pharmaceuticals, Inc. [Member]
Asset Purchase Agreement [Member]
Management Services Agreement [Member]
Dr. Lindstrom [Member]
Trademarks [Member]
Notes Payable [Member]
Adjustments for New Accounting Pronouncements [Axis]
ASU- 2016-02 [Member]
Geographical [Axis]
San Diego [Member]
Irvine [Member]
Ledgewood [Member]
Common Stock Warrants Two [Member]
Common Stock Warrants One [Member]
Plan Name [Axis]
2017 Incentive Stock and Awards Plan [Member]
Employees and Consultant [Member]
Mayfield Pharmaceuticals, Inc. [Member]
Elle Pharmaceutical, LLC [Member]
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Joinder and Amendment [Member]
Allergan USA, Inc. [Member]
Board of Directors [Member]
Ownership [Axis]
Stowe Pharmaceuticals, Inc. [Member]
Park Compounding, Inc. and Noice Rx, LLC [Member]
Stock Option [Member]
Exercise Price $1.70 to $4.17 [Member]
Exercise Price $1.70 to $3.20 [Member]
TGV-Gyneconix, LLC [Member]
TGV-Ophthalnix, LLC [Member]
Variable Rate [Axis]
London Inter-Bank Offered Rate [Member]
Margin Rate [Member]
Restricted Stock [Member]
Mark Baum, CEO [Member]
Andrew Boll, CFO [Member]
TGV-Health, LLC [Member]
Licensing Agreement [Member]
Antidilutive Securities [Axis]
Stock Options, Unvested RSUs and Warrants [Member]
Stock Options [Member]
Two Asset Purchase and License Agreement [Member]
Customer Relationships, Trade Name and State Pharmacy Licenses [Member]
Park Compounding, Inc. [Member]
State Pharmacy Licenses [Member]
Term Loan and Security Agreement [Member]
SWK Funding LLC [Member]
SWK Loan Agreement [Member]
Nashville [Member]
Injectable Asset Purchase Agreement [Member]
Presbyopia Asset Purchase Agreement [Member]
Class of Stock [Axis]
Series A Preferred Stock [Member]
Lease Contractual Term [Axis]
Capital Lease [Member]
Operating Lease [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filer
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current assets
Cash and cash equivalents, including restricted cash of $200
Investment in Eton Pharmaceuticals
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Investment
Goodwill
TOTAL ASSETS
LIABILITIES AND EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of note payable, net of unamortized debt discount
Current portion of operating lease obligations
Current portion of finance lease obligations, net of unamortized discount
Total current liabilities
Operating lease obligations, net of current portion
Finance lease obligations, net of current portion and unamortized discount
Accrued expenses, net of current portion
Note payable, net of current portion and unamortized debt discount
TOTAL LIABILITIES
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 25,526,931 and 24,339,610 shares issued and outstanding at December 31, 2019 and 2018, respectively
Additional paid-in capital
Accumulated deficit
TOTAL HARROW HEALTH, INC STOCKHOLDERS' EQUITY
Noncontrolling interests
TOTAL EQUITY
TOTAL LIABILITIES AND EQUITY
Statement of Financial Position [Abstract]
Restricted cash
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenues:
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Impairment of long-lived assets
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Investment (loss) gain, net
Loss on sale of assets
Other income, net
Total other income, net
Income (loss) before income taxes
Income tax benefit, net
Total net income (loss) including noncontrolling interests
Net loss attributable to noncontrolling interests
Net income attributable to Harrow Health, Inc.
Basic net income per share of common stock
Diluted net income per share of common stock
Weighted average number of shares of common stock Outstanding, basic
Weighted average number of shares of common stock Outstanding, diluted
Balance
Balance, shares
Issuance of common stock in connection with: Exercise of warrants
Issuance of common stock in connection with: Exercise of warrants, shares
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding, shares
Issuance of common stock in connection with: Sale of stock, net of costs (ATM)
Issuance of common stock in connection with: Sale of stock, net of costs (ATM), shares
Issuance of common stock in connection with: Stock-based payment for services provided
Issuance of common stock in connection with: Stock-based payment for services provided, shares
Issuance of common stock in connection with: Exercise of employee stock options, net of tax withholding
Issuance of common stock in connection with: Exercise of employee stock options, net of tax withholding
Stock-based compensation expense
Net income (loss)
Balance
Balance, shares
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income (includes non-controlling interests)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment
Amortization of intangible assets
Amortization of operating lease right-of-use assets
Amortization of debt issuance costs and discount
Investment (gain)/loss
Loss on sale, impairments and disposal of assets
Stock based payment for services provided
Stock-based compensation
Changes in assets and liabilities, net of impairments and disposals:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH PROVIDED BY OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable
Proceeds on sale and disposal of assets
Investment in patent and trademark assets
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations
Payments on Park deferred acquisition obligation
Principal payments on note payable
Payments of costs related to amendment of note payable
Net proceeds from ATM sales of common stock
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's and options
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES
NET (DECREASE) INCREASE IN, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
Restricted cash
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment included in accounts payable
Right-of-use asset obtained in exchange for lease obligation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Revenue from Contract with Customer [Abstract]
Revenues
Investments, Debt and Equity Securities [Abstract]
Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions
Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions
Restricted Cash [Abstract]
Restricted Cash
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Leases [Abstract]
Leases
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation
Income Tax Disclosure [Abstract]
Income Taxes
Retirement Benefits [Abstract]
Employee Savings Plan
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Use of Estimates
Liquidity
Segments
Noncontrolling Interests
Revenue Recognition and Deferred Revenue
Cost of Sales
Research and Development
Debt Issuance Costs and Debt Discount
Intellectual Property
Income Taxes
Cash and Cash Equivalents
Concentrations of Credit Risk
Investment in Eton Pharmaceuticals, Inc.
Accounts Receivable
Inventories
Investment in Melt Pharmaceuticals, Inc.
Investment in Surface Pharmaceuticals, Inc.
Property, Plant and Equipment
Business Combinations
Goodwill and Intangible Assets
Impairment of Long-Lived Assets
Park Restructuring
Fair Value Measurements
Stock-Based Compensation
Basic and Diluted Net Income Per Common Share
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic Earnings Per Common Share
Schedule of Diluted Common Equivalent Shares
Schedule of Diluted Earnings Per Common Share
Schedule of Disaggregated Revenue
Schedule of Condensed Income Statement
Schedule of Condensed Balance Sheet
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property, Plant and Equipment
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Goodwill
Schedule of Accounts Payable and Accrued Expenses
Summary of Future Minimum Payments
Schedule of Future Lease Payment Under Operating Leases
Schedule of Future Lease Payment Under Finance Lease
Schedule of Future Minimum Lease Payments Under Operating Lease and Finance Lease
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumptions
Schedule of Stock Option Outstanding and Exercisable
Schedule of Restricted Stock Units Activity
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Provision for Income Taxes
Schedule of Income Tax Reconciliation
Schedule of Deferred Tax Assets and Liabilities
Schedule of Change in Unrecognized Tax Benefits
Schedule of Segment Net Revenues, Segment Operating Expenses and Segment Contribution
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Statistical Measurement [Axis]
Ownership percentage
Consolidation basis, description
Cash resources and restricted investments, marketable securities
Number of segments
Non-controlling interest description
FDIC insured amount
Gain on deconsolidation amount
Net loss on equity
Number of shares issued
Stock price per shares
Stock issued during period value
Gain (loss) on investment
Fair market value of investments
Milestone payments received
Royalty fee, percentage
Payment to acquire patent rights
Accounts receivable, net of allowance for doubtful accounts
Proceeds from issuance of preferred stock
Number of shares owned
Carrying value of investments
Property and equipment estimated useful life
Intangible assets estimated useful life
Non-cash impairment costs
Severance packages and other costs
Antidilutive securities
Number of shares vested during the period
Right of use asset
Operating and finance leases
Numerator - net income
Denominator - weighted average number of shares outstanding, basic
Net income per share, basic
Dilutive common equivalent shares
Weighted average number of shares outstanding, basic
Dilutive common equivalents
Denominator - number of shares used for diluted earnings per share computation
Net income per share, diluted
Total Revenues
Royalty payment percentage on net sales
Administrative expenses
Reimbursable expenses due
Proceeds from related party payments
Revenues, net
Loss from operations
Net loss
Current assets
Non current assets
Total assets
Total liabilities
Total preferred stock and stockholders' equity
Total liabilities and stockholders' equity
Total stockholders equity
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Receivable due from related party
Deposits and other current assets
Total prepaid expenses and other current assets
Computer software and hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Property, plant and equipment, gross
Accumulated depreciation and amortization
Property, plant and equipment, Net
Impairment of intangible assets
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Impairment
Net Carrying value
2020
2021
2022
2023
2024
Thereafter
Intangible assets
Beginning balance
Impairment of Park goodwill
Ending balance
Accounts payable
Other accrued expenses
Deferred rent
Accrued interest
Accrued exit fee for note payable
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Debt principal amount
Loan bear interest at variable rate
Loan bear interest at variable rate, description
Repayment of debt
Debt due date description
Incurred expense debt
Liability of final fee included in accrued expenses
Warrant to purchase of common stock
Warrant exercise price per share
Warrant term
Fair value warrant adjustments
Fair value assumptions, measurement input, per share
Fair value assumptions, measurement input, percentages
Deconsolidation percentage
Legal and lender costs
Amortization of debt discount
2020
2021
2022
2023
Total minimum payments
Less: amount representing interest
Notes payable, gross
Less: unamortized discount
Notes payable
Less: current portion, net of unamortized discount
Operating lease space
Operating lease expires date
Lease term
Lease term description
Weighted average incremental borrowing rate, operating lease
Weighted average remaining lease term, operating lease
Increase in operating lease right-of-use assets
Decrease in accounts payable and accrued expenses
Increase in operating lease liability
Operating lease right use of assets
Operating lease liability
Cash paid in operating lease liability
Operating lease expense
Weighted average incremental borrowing rate, finance lease
Weighted average remaining lease term, finance lease
Debt discount amortization
Depreciation expenses
Cash paid for interest expenses
2020
2021
2022
2023
2024
Thereafter
Total minimum lease payments
Less: amount representing interest payments
Total operating lease liabilities
Less: current portion, operating lease liabilities
Operating lease liabilities, net of current portion
2020
2021
2022
2023
2024
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payments
Less: current portion, finance lease obligation
Finance lease obligation, net of current portion
LeaseContractualTermAxis [Axis]
2019
2020
2021
2022
2023
Thereafter
Financing lease payment
Less: Amounts representing interest
Less: Amounts representing unamortized discount
Total obligation under capital leases
Less: Current portion of capital leases
Long term capital lease obligation
2019
2020
2021
2022
2023
Operating lease payment
Shares issued of restricted common stock, shares
Accrued royalty expense
Fair value of restricted common stock issued
Number of shares sold under the agreement
Proceeds from sale of common stock approximately
Sales commission and offering expenses
Warrants exercise price
Proceeds from issuance of warrant
Number of warrants exercised
Number of options exercised
Options exercise price, minimum
Options exercise price, maximum
Common stock withheld for payroll tax withholdings
Common stock withheld for payroll tax withholdings, value
Proceeds from issuance of common stock
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Maximum number of common stock issuance under the plan
Shares available for future issuances
Closing price of common stock price per share
Intrinsic value of options exercised
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Forfeiture factor, percentage
Unrecognized compensation expense related to unvested stock options granted under the plan
Expense expected to recognize over the weighted-average remaining vesting period
Number of shares issued for acquisition
Number of common stock issued for consultants services
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeited
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeited
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility, minimum
Expected volatility, maximum
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number of RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, Ending balance
Stock based compensation related to equity instruments granted to related parties
Number of Shares Warrants Outstanding, beginning balance
Number of Shares Warrants Outstanding, Granted
Number of Shares Warrants Outstanding, Exercised
Number of Shares Warrants Outstanding, Expired
Number of Shares Warrants Outstanding and Exercisable, ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted Avg. Exercise Price, Outstanding, beginning balance
Weighted Avg. Exercise Price, Exercised
Weighted Avg. Exercise Price, Expired
Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Deferred tax asset valuation allowance
Federal net operating loss carryforwards
Federal research and development tax credits
Federal research and development tax credits expiration date
State net operating loss carryforwards
State net operating loss expiration date
State research and development tax credits
Current: Federal
Current: State
Total current
Deferred: Federal
Deferred: State
Deferred: Change in valuation allowance
Total deferred
Income tax provision (benefit)
U.S. federal statutory tax rate
Benefit of lower tax brackets
State tax benefit, net
Research and development credits
Employee stock-based compensation
Loss on debt conversion
Capitalization of Subsidiary
Change in Rate
Other
Valuation allowance
Effective income tax rate
NOLs
Depreciation and amortization
Other
Research and development credits
Deferred stock compensation
Basis Difference in Melt
Basis Difference in Surface
Basis Difference in Eton
Capital Losses
Park stock purchase identifiable intangibles
Limitation Under 163(j)
ASC 842 Lease Liability
ASC 842 ROU Asset
Total deferred tax assets, net
Valuation allowance
Net deferred tax liabilities
UTB, Beginning balance
Additions for tax positions related to current year
Additions/(reductions) for tax positions related to prior years
UTB, Ending balance
Percentage of salary deposits in tax deferred investment account
Percentage of contributions made by the company
Contributions by the company
Accrued damages
Damages low claim rate, percentage
Litigation amount paid
Lost profit damages
Commission payments, percentage
Additional paid in capital and stock based payments
Commission expense incurred
Business acquisition description
Accounts payable and accrued expenses
Royalty payments
Royalty payment description
Net sales
Milestone payment in cash
Milestone payments on payables
Number of reportable segment
Maximum percentage of sales derived from large number of customer
Percentage of drug and chemical purchases from three main suppliers
Gross profit
Segment contribution
Amortization
Asset sales and impairments, net
Operating loss
Amended and Restated Certificate of Incorporation [Member]
Amended Lease Agreement [Member]
Andrew R Boll [Member]
Asset Purchase Agreement [Member]
Billing and Collection Agreement [Member]
Cantor Fitzgerald & Co [Member]
Cash and cash equivalents and Restricted cash at end of period.
Cashless Warrants Exercise [Member]
Closing price of common stock price per share.
Commercial Lease Agreement [Member]
Commission payments, percentage.
Common Stock Warrant One [Member]
Common Stock Warrants [Member]
Consultant
Consultants Employees and Directors [Member]
Convertible Note [Member]
December 31, 2017 [Member]
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Dr. Lindstrom [Member]
8.00% Convertible Senior Secured Note [Member]
Elle Pharmaceutical, LLC [Member]
Employees and Consultants [Member]
Employees [Member]
Eton License Agreements [Member]
Eton Pharmaceuticals, Inc. [Member]
Eton Pharmaceuticals, Inc. One [Member]
Eton Pharmaceuticals, Inc. Two [Member]
Eton Pharmaceuticals [Member]
Exchange Agreement [Member]
Final Payment [Member]
Forfeiture factor, percentage.
General And Administrative [Member]
Imprimis TX [Member]
Initial Payment [Member]
Investments And Agreements - Related Party Transactions [Text Block]
John P Saharek [Member]
Klarity License Agreement [Member]
LSAF Loan [Member]
Lease Agreement [Member]
Lender Warrants [Member]
Lender Warrants One [Member]
License Agreement [Member]
License Revenue [Member]
Licenses [Member]
Life Sciences Alternative Funding LLC [Member]
Liquidity Disclosure [Policy Text Block]
Livernois [Member]
Loan Agreement [Member]
Loan and Security Agreement [Member]
London Inter-Bank Offered Rate [Member]
Management Services Agreement [Member]
Management Services Agreement [Member]
Non Employee Directors [Member]
Note Payable [Member]
Note Purchase Agreement [Member]
Notes Payable [Member]
Options granted to employees
Other [Member]
PIPE Investor and Placement Agent Warrants [Member]
Percentage of drug and chemical purchases from three main suppliers.
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Pharmacy Solutions Central, LLC [Member]
Placement Agent Warrants [Member]
Previously Authorized Shares [Member]
Product Sales, Net [Member]
Range five [member]
Range four [member].
Range one [member].
Range Six [Member]
Range three [member].
Range two [member].
Recently Adopted Accounting Pronouncements [Policy Text Block]
Reconciliation of Cash and cash equivalents.
Reconciliation Restricted cash.
Richard L. Lindstrom, M.D [Member]
Royalty payment description.
SWK Loan Agreement [Member]
SWK Warrants [Member]
Sales Agreement [Member]
Sales and Marketing Agreements [Member]
Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Second Payment [Member]
Segment contribution.
Selling And Marketing [Member]
Selling, General and Administrative [Member]
Settlement Agreement [Member]
Settlement Warrants [Member]
State Pharmacy Licenses [Member]
StockOptionPlanMember
Stock Option Plan [Member]
Stock Options [Member]
Stock Purchase Agreement [Member]
Surface License Agreements [Member]
Surface Pharmaceuticals Inc [Member]
Surface Pharmaceuticals Inc One [Member]
Surface Pharmaceuticals Inc Two [Member]
Surface Pharmaceuticals [Member]
Surface Series A Stock [Member]
Tax Reform [Member]
Third Party [Member]
2007 Incentive Stock and Awards Plan [Member]
2017 Incentive Stock and Awards Plan [Member]
unvested RSUs [Member]
Warrants issuance date.
Warrants Issued To Investor Relations Consultant One [Member]
Melt Pharmaceuticals [Member]
Stock issued during period for exercise of warrants.
Stock issued during period shares for exercise of warrants.
Stock issued during period for vesting of restricted stock unit net of tax withholding.
Stock issued during period for vesting of restricted stock unit net of tax withholding shares.
Noncontrolling Interests.
Melt Series A Stock [Member]
Melt Pharmaceuticals, Inc. [Member]
Royalty payment percentage on net sales.
Finite Lived Intangible Assets Impairment.
San Diego [Member]
Irvine [Member]
Ledgewood [Member]
Cash paid in operating lease liability.
Common Stock Warrants One [Member]
Mayfield Pharmaceuticals, Inc. [Member]
May 31, 2019 [Member]
Investment in Melt Pharmaceuticals, Inc. [Text Block]
Investment in Surface Pharmaceuticals, Inc. [Text Block]
Net sales of product.
Property Available for Financing Lease [Member]
2017 Plan [Member]
Operating Lease [Member]
Payments of costs related to amendment of note payable.
Term Loan and Security Agreement [Member]
SWK Funding LLC [Member]
Margin Rate [Member]
Employees and Consultant [Member]
Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.
Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price.
Share based compensation arrangements by share based payment award non options equity instruments exercised in period weighted average exercise price.
Damages low claim rate, percentage.
Allergan USA, Inc [Member]
Stowe Pharmaceuticals, Inc. [Member]
Deconsolidation percentage.
Board of Directors [Member]
Impairment and disposal of long-lived assets.
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU’s and options.
Restructuring [Policy Text Block]
TGV-Ophthalnix, LLC [Member]
Consolidation basis, description.
Park and Noice Rx, LLC [Member]
Customer Relationships, Trade Name and State Pharmacy Licenses [Member]
Number of warrants exercised.
Common Stock Warrants Two [Member]
TGV-Gyneconix, LLC [Member]
Consultants and Harrow Employees [Member]
Weighted average incremental borrowing rate, finance lease.
Weighted average incremental borrowing rate, operating lease.
Increase in operating lease liability.
Increase in operating lease right-of-use assets.
Common stock withheld for payroll tax withholdings.
Common stock withheld for payroll tax withholdings, value.
Mark Baum, CEO [Member]
Andrew Boll, CFO [Member]
Right-of-use asset obtained in exchange for lease obligation.
Restricted Cash [Text Block]
Cost of sales [Policy Text Block]
TGV-Health, LLC [Member]
Cash resources and restricted investments, marketable securities.
Milestone payments received.
Royalty fee, percentage.
Payment to acquire patent rights.
Park Compounding, Inc. and Noice Rx, LLC [Member]
Stock Options, Unvested RSUs and Warrants [Member]
Incremental Common Shares Attributable to Dilutive common equivalents.
Two Asset Purchase and Licenese Agreement [Member]
Park Compounding, Inc. [Member]
Joinder and Amendment [Member]
Nashville [Member]
Sales commission and offering expenses.
Number of shares warrants outstanding and exercisable, ending balance.
Weighted avg. exercise price, expired.
Warrants exercisable.
Federal Research And Development Tax Credits Expiration Date.
Federal Research And Development Tax Credits.
State net operating loss expiration date.
State Research And Development Tax Credits.
Deferred Income Change In Valuation Allowance.
Effecticve Income Tax Rate Benefit Of Lower Tax Brackets.
Effective Income Tax Rate Loss On Debt Conversion.
Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.
Basis Difference in Melt.
Basis Difference in Surface.
Basis Difference in Eton.
Capital losses.
Limitation Under 163(j).
ASC 842 Lease Liability.
ASC 842 ROU Asset.
Percentage of salary deposits in tax deferred investment account.
Additional paid in capital and stock based payments.
Milestone payment in cash.
Milestone payments on payables.
Injectable Asset Purchase Agreement [Member]
Presbyopia Asset Purchase Agreement [Member]
Amortization of operating lease right-of-use assets.
Schedule of Future Minimum Lease Payments Under Operating Lease and Finance Lease [Table Text Block]
Operating and finance leases.
Finance lease liability interest excess amount.
Capital Lease [Member]
Effective Income Tax Rate Loss on capitalization of subsidiary.
Lease contractual term [Axis]
StockOptionPlanOneMember
ManagementServicesAgreementMember
Assets, Current
Liabilities, Current
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Cost of Goods and Services Sold
Operating Expenses
Nonoperating Income (Expense)
Stock Issued During Period, Value, Employee Benefit Plan
Gain (Loss) on Disposition of Assets
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Contract with Customer, Liability
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Intangible Assets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Finance Lease, Principal Payments
Payments of Financing Costs
Repayments of Notes Payable
PaymentsOfAmendmentRelatedCostsNotesPayable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
ReconciliationRestrictedCash
StockOption5Member
Inventory Disclosure [Text Block]
Income Tax, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Goodwill, Impairment Loss
Accounts Payable and Accrued Liabilities
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
Long-term Debt
Interest Payable, Current
Debt Instrument, Unamortized Discount
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months
Lessee, Operating Lease, Liability, Payments, Due Year Two
Lessee, Operating Lease, Liability, Payments, Due Year Three
Lessee, Operating Lease, Liability, Payments, Due Year Four
Lessee, Operating Lease, Liability, Payments, Due Year Five
Lessee, Operating Lease, Liability, Payments, Due after Year Five
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, Payments, Due Next Twelve Months
Finance Lease, Liability, Payments, Due Year Two
Finance Lease, Liability, Payments, Due Year Three
Finance Lease, Liability, Payments, Due Year Four
Finance Lease, Liability, Payments, Due Year Five
Finance Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, Payments, Due after Year Five
FinanceLeaseLiabilityInterestExcessAmount
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1
Current Income Tax Expense (Benefit)
Deferred Income Tax Expense (Benefit)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Deferred Tax Assets, Tax Deferred Expense, Other
Deferred Tax Assets, Tax Credit Carryforwards, General Business
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net
Unrecognized Tax Benefits
Accounts Payable and Other Accrued Liabilities